Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) Shares Outstanding (Weighted Average) (2020 - 2023)

Candel Therapeutics' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $28.9 million for Q3 2023.

  • For Q3 2023, Shares Outstanding (Weighted Average) changed 0.1% year-over-year to $28.9 million; the TTM value through Sep 2023 reached $28.9 million, changed 0.1%, while the annual FY2022 figure was $28.8 million, 52.72% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2023 was $28.9 million at Candel Therapeutics, roughly flat from $28.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $28.9 million in Q1 2023 and bottomed at $11.6 million in Q2 2020.
  • The 4-year median for Shares Outstanding (Weighted Average) is $26.0 million (2021), against an average of $21.6 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) skyrocketed 146.57% in 2022 before it grew 0.1% in 2023.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $11.6 million in 2020, then surged by 62.49% to $18.9 million in 2021, then skyrocketed by 52.72% to $28.8 million in 2022, then grew by 0.33% to $28.9 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Shares Outstanding (Weighted Average) are $28.9 million (Q3 2023), $28.9 million (Q2 2023), and $28.9 million (Q1 2023).